Amneal Reports Second Quarter 2025 Financial Results

Core Insights - Amneal Pharmaceuticals reported a net revenue of $725 million for Q2 2025, reflecting a 3% increase from $702 million in Q2 2024. The company also achieved a GAAP net income of $22 million, up from $6 million in the same quarter last year [1][4][3]. Financial Performance - The adjusted EBITDA for Q2 2025 was $184 million, marking a 13% increase compared to the same period in 2024 [4]. - Diluted income per share rose to $0.07 in Q2 2025 from $0.02 in Q2 2024, while adjusted diluted EPS increased by 56% to $0.25 from $0.16 [5][4]. Revenue Breakdown - Specialty net revenue surged by 23%, driven by key branded products such as CREXONT®, RYTARY®, and UNITHROID® [3]. - Affordable Medicines net revenue saw a 1% increase, attributed to strong performance in the complex product portfolio and new product launches, although this was partially offset by supply timing issues [3]. - AvKARE net revenue decreased by 4%, impacted by lower revenue in the distribution channel despite growth in government label sales [3]. Guidance and Outlook - The company raised its full-year 2025 guidance, maintaining net revenue expectations between $3.0 billion and $3.1 billion, while increasing adjusted EBITDA guidance to $665 million - $685 million from the previous $650 million - $675 million [7][8]. Debt Refinancing - Amneal completed a comprehensive debt refinancing on August 1, 2025, entering into $2.1 billion of new seven-year Term B loans and issuing $600 million in senior secured notes due 2032. This refinancing is expected to yield substantial interest cost savings and extend maturities to 2032 [10][2].